Advertisement

How I Perform ALA-Photodynamic Therapy in My Practice

  • Dore J. GilbertEmail author
Chapter

Abstract

ALA-PDT is a safe and efficacious therapy for the treatment and rejuvenation of sun-damaged skin, AKs and actinic porokeratoses, and acne. Clearance rates are typically very high with only several treatments. ALA-PDT does not require prolonged application and contact time compared with chemotherapeutic agents, resulting in reduced adverse events. Further, compared with other topical or systemic therapies, ALA-PDT is cost effective when applied to multiple lesions or broad areas. There may be some disadvantages associated with ALA-PDT including the downtime involved due to sun avoidance following a treatment, and the small-to-moderate risk of postinflammatory hyperpigmentation that directly relates to your skin type. In addition, many patients require multiple treatments to produce the desired results. Overall, ALA-PDT therapy provides a suitable alternative for treating sun-damaged skin, AKs, and acne.

Keywords

Sebaceous Gland Actinic Keratosis Light Therapy Intense Pulse Light Actinic Keratosis Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ericson MB, Wennberg AM, Larko O. Review of photo­dynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag. 2008;4:1–9.PubMedGoogle Scholar
  2. 2.
    Stritt A, Merk HF, Braathen LR, von Felbert V. Photodynamic therapy in the treatment of actinic keratosis. Photochem Photobiol. 2008;84:388–98.PubMedCrossRefGoogle Scholar
  3. 3.
    Tierney E, Barker A, Ahdout J, Hanke CW, Roy RL, Kouba DJ. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg. 2009;35:725–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Taylor MN, Gonzalez ML. The practicalities of photo­dynamic therapy in acne vulgaris. Br J Dermatol. 2009;160:1140–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Nybaek H, Jemec GB. Photodynamic therapy in the treatment of rosacea. Dermatology. 2005;211:135–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol. 2006;5:6–8.PubMedGoogle Scholar
  7. 7.
    Orringer JS, Hammerberg C, Hamilton T, et al. Molecular effects of photodynamic therapy for photo­aging. Arch Dermatol. 2008;144:1296–302.PubMedCrossRefGoogle Scholar
  8. 8.
    Poh-Fitzpatrick MB. Porphyrias, photosensitivity and phototherapy. Methods Enzymol. 2000;319:485–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA phtochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol. 2004;4:1–11.CrossRefGoogle Scholar
  10. 10.
    Abramson AL, Aivi A, Mullooly VM. Clinical exacerbation of systemic lupus erythematosus after photodynamic therapy of laryngotracheal papillomatosis. Lasers Surg Med. 2005;13:677–9.CrossRefGoogle Scholar
  11. 11.
    Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med. 2000;28:537–48.PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor EL, Brown SB. The advantages of aminolevulinic acid photodynamic therapy in dermatology. J Dermatol Treat. 2002;13:S3–11.CrossRefGoogle Scholar
  13. 13.
    Barr H, Kendall C, Reyes-Goddard J, Stone N. Clinical aspects of photodynamic therapy. Sci Prog. 2002;85:131–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Szeimies RM, Landthaler M. Photodynamic therapy and fluorescence diagnosis of skin cancers. Recent Results Cancer Res. 2002;160:240–5.PubMedGoogle Scholar
  15. 15.
    Szeimies RM, Calzavara-Pinton PG, Karrer S, et al. Topical photodynamic therapy in dermatology. J Photochem Photobiol. 1996;36:213–9.CrossRefGoogle Scholar
  16. 16.
    Muller S, Walt H, Dobler-Girdziunaite D, et al. Enhanced photodynamic effects using fractionated laser light. J Photochem Photobiol B. 1998;42:67–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44 suppl 1:S1–26.PubMedCrossRefGoogle Scholar
  18. 18.
    Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol. 2000;42:18–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22:189–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis – an update. Br J Dermatol. 2007;157 suppl 2:18–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Ehriq T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg. 2006;32:1261–5.CrossRefGoogle Scholar
  25. 25.
    Kang BD, Kye YC, Kim SN. Disseminated superficial actinic porokeratosis with both typical and prurigo nodularis-like lesions. J Dermatol. 2001;28:81–5.PubMedGoogle Scholar
  26. 26.
    Herranz P, Pizarro A, De Lucas R, et al. High incidence of porokeratosis in renal transplant recipients. Br J Dermatol. 1997;136:176–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Guenova E, Hoetzenecker W, Metzler G, Rocken M, Schaller M. Multicentric Bowen disease in linear porokeratosis. Eur J Dermatol. 2007;17:430–9.Google Scholar
  28. 28.
    Sasson M, Krain AD. Porokeratosis and cutaneous malignancy. A review. Dermatol Surg. 1996;22:339–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Danby W. Treatment of porokeratosis with fluorouracil and salicylic acid under occlusion. Dermatol Online J. 2003;9:33.PubMedGoogle Scholar
  30. 30.
    Harrison PV, Stollery N. Disseminated superficial actinic porokeratosis responding to calcipotriol. Clin Exp Dermatol. 1994;19:95.PubMedCrossRefGoogle Scholar
  31. 31.
    Jain S. Successful treatment of porokeratosis of Mibelli with imiquimod 5% cream. Clin Exp Dermatol. 2006;97:77–8.Google Scholar
  32. 32.
    Garcia-Navarro X, Garces JR, Baselga E, Alomar A. Linear porokeratosis: excellent response to photodynamic therapy. Arch Dermatol. 2009;145:526–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Gilbert DJ. Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol. 2005;4:161–3.PubMedGoogle Scholar
  34. 34.
    Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140:41–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45:96–104.PubMedCrossRefGoogle Scholar
  36. 36.
    Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed. 2003;19:134–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Goldman MP, Boyce S. A single-center study of amino­levulinic acid and 417 nm photodynamic ­therapy in the treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2003;2:393–6.PubMedGoogle Scholar
  38. 38.
    Pollock B, Turner D, Stringer MR, et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol. 2004;151:616–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy for acne vulgaris with topical 5-aminolevulinic acid. Arch Dermatol. 2000;136:1093–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photody­namic therapy of acne vulgaris with topical delta aminolevulinic acid and incoherent light in Japanese patients. Br J Dermatol. 2001;144:575–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA, Carter LN. The use of a novel intense pulsed light and heat source and ALA-PDT in the treatment of moderate to severe inflammatory acne vulgaris. J Drugs Dermatol. 2004;3 suppl 6:S15–9.PubMedGoogle Scholar
  42. 42.
    Schaller M, Loewenstein M, Borelli C, et al. Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br J Dermatol. 2005;153:66–71.PubMedCrossRefGoogle Scholar
  43. 43.
    Gold MH. Efficacy of lasers and PDT for the treatment of acne vulgaris. Skin Therapy Lett. 2007;12:1–6.Google Scholar
  44. 44.
    Akaraphanth R, Kanjanawanitchkul W, Gritiyarangsan P. Efficacy of ALA-PDT vs blue light in the treatment of acne. Photodermatol Photoimmunol Photomed. 2007;23:186–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Hongcharu W, Taylor CR, Chang Y, et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol. 2000;115:183–92.PubMedCrossRefGoogle Scholar
  46. 46.
    Taub AF. Photodynamic therapy for the treatment of acne: a pilot study. J Drugs Dermatol. 2004;3:S10–4.PubMedGoogle Scholar
  47. 47.
    Goldman MP. Using 5-aminolevulinic acid to treat acne and sebaceous hyperplasia. Cosmetic Dermatol. 2003;16:57–8.Google Scholar
  48. 48.
    Taub AF. A comparison of intense pulsed light, combination radiofrequency and intense pulsed light, and blue light in photodynamic therapy for acne vulgaris. J Drugs Dermatol. 2007;6:1010–6.PubMedGoogle Scholar
  49. 49.
    Rojanamatin J, Choawawanich P. Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg. 2006;32:991–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Santos MA, Belo VG, Santos G. Effectiveness of photo­dynamic therapy with topical 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone in the treatment of acne vulgaris: comparative study. Dermatol Surg. 2005;31:910–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Alexiades-Armenakas MR. Long-pulsed dye laser-mediated photodynamic therapy combined with topical therapy for mild-to-severe comedonal, inflammatory, or cystic acne. J Drugs Dermatol. 2006;5:45–55.PubMedGoogle Scholar
  52. 52.
    Gilbert DJ. Treatment of sebaceous hyperplasia. In: Goldman MP, editor. Photodynamic therapy. 2nd ed. Philadelphia: Saunders; 2008.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.University of CaliforniaIrvineUSA
  2. 2.Newport Dermatology and Laser AssociatesNewport BeachUSA

Personalised recommendations